Table 1.
Demographics of Patients Who Underwent Liver Transplantation (LT) Over a 3-Year Period Classified by Human Herpesvirus 6 (HHV-6) Serostatus Prior to LT (January 2013–December 2015)
| Characteristics | Overalla (n = 101) | HHV-6 Seropositive (n = 62) | HHV-6 Seronegative (n = 34) | P-valuec |
|---|---|---|---|---|
| Female | 50 (49.5%) | 31 (50%) | 17 (50%) | .99 |
| Median age in years (IQR) | 3.12 (1.2, 9.2) | 5.7 (1.6, 13.1) | 1.6 (0.79, 2.7) | <.0001 |
| Median donor age, years (IQR) | 7 (3, 16) | 7.5 (3, 16) | 4 (2,12.8) | .2 |
| Race | .48 | |||
| African American | 15 (14.9%) | 10 (16%) | 4 (11.8%) | |
| Caucasian | 38 (37.6%) | 23 (37%) | 14 (41.2%) | |
| Hispanic | 38 (37.6%) | 21 (34%) | 14 (41.2%) | |
| Asian | 5 (4.9%) | 5 (8%) | 0 | |
| Unknown | 5 (4.9%) | 3 (4.8%) | 2 (5.8%) | |
| Primary liver disease, N (%) | .04 | |||
| Biliary atresia | 36 (35.6%) | 20 (32%) | 16 (47%) | |
| Other cholestatic diseaseb | 15 (14.8%) | 11 (17.7%) | 4 (11.7%) | |
| Fulminant liver failure | 7 (6.9%) | 5 (8%) | 0 | |
| Autoimmune disease | 5 (4.9%) | 3 (4.8%) | 0 | |
| Metabolic | 13 (12.9%) | 5 (8%) | 8 (23.5%) | |
| Tumors/cancer | 15 (14.8%) | 9 (14.5%) | 5 (14.7%) | |
| Others | 10 (9.9%) | 9 (14.5%) | 1 (2.9%) | |
| Insurance private, N (%) | 39 (38.6%) | 23 (37.1%) | 13 (38.2%) | .97 |
aSerology was unavailable for 4 patients and equivocal for 1 patient.
bOther cholestatic liver diseases include progressive familial intrahepatic cholestasis (PFICs), Alagille syndrome, Alpha-1 antitrypsin deficiency, Wilson disease, and cystic fibrosis.
cComparison of seropositive with seronegative groups.